Perospiron

Iz Wikipedije, slobodne enciklopedije
Perospiron
(IUPAC) ime
(3aR,7aS)-24-[4-(1,2-benzizotiazol-3-il)piperazin-1-il]butil}heksahidro-1H-izoindol-1,3(2H)-dion
Klinički podaci
Robne marke Lulan
AHFS/Drugs.com Internacionalno ime leka
Identifikatori
CAS broj 150915-41-6
ATC kod nije dodeljen
PubChem[1][2] 115368
ChemSpider[3] 16737064
UNII N303OK87DT YesY
Hemijski podaci
Formula C23H30N4O2S 
Mol. masa 426,57 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Poluvreme eliminacije 2-2,5 sata
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status Prescription only
Način primene Oralnot

Perospiron (Lulan) je atipični antipsihotik iz azapironske hemijske klase.[4] Njega je razvila japanska kompanija Dajnipon sumitomo farma 2001 za lečenje šizofrenije i akutne bipolarne manije.[5][6] Perospiron deluje kao parcijalni agonist 5-HT1A receptora, inverzni agonist 5-HT2A receptora i antagonist D2, D4 i α1-adrenergičkog receptora.[7][8][9][10]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs 15 (4): 329–37; discussion 338. PMID 11463136. doi:10.2165/00023210-200115040-00006. 
  5. de Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)". Current Opinion in Investigational Drugs (London, England : 2000) 3 (1): 121–9. PMID 12054062. 
  6. "Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma". http://www.ds-pharma.co.jp/english/news/sumitomo_2001/no_002.html. 
  7. Hirose A, Kato T, Ohno Y et al. (July 1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions". Japanese Journal of Pharmacology 53 (3): 321–9. PMID 1975278. doi:10.1254/jjp.53.321. 
  8. Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). "Binding profile of SM-9018, a novel antipsychotic candidate". Japanese Journal of Pharmacology 54 (4): 478–81. PMID 1982326. doi:10.1254/jjp.54.478. 
  9. Odagaki Y, Toyoshima R (2007). "5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes". Clinical and Experimental Pharmacology & Physiology 34 (5–6): 462–6. PMID 17439416. doi:10.1111/j.1440-1681.2007.04595.x. 
  10. Seeman P, Tallerico T (March 1998). "Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors". Molecular Psychiatry 3 (2): 123–34. PMID 9577836. doi:10.1038/sj.mp.4000336. 

Vidi još[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).